-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Reiterates Neutral on SpringWorks Therapeutics, Maintains $47 Price Target

Benzinga·05/12/2025 14:07:13
Listen to the news
Guggenheim analyst Michael Schmidt reiterates SpringWorks Therapeutics (NASDAQ:SWTX) with a Neutral and maintains $47 price target.